Supriya Lifescience Ltd
NSE: SUPRIYA BSE: 543434
₹684.65
(-0.76%)
Wed, 25 Feb 2026, 07:52 am
Market Cap55.56B
PE Ratio29.74
Dividend0.14
Health Technology
Pharmaceuticals: Major
24.5KCompany History
2008
- The Company was incorporated upon its conversion from a partnership firm to a public limited company.
- The Company commenced operations.
2009
- Production of Ketamine Hydrochloride started.
2010
- CEP (Certificate of Sustainability) was granted for Chlorphenamine Maleate.
2011
- IDL was granted for Chlorphenamine Maleate.
2013
- COFEPRIS and KFDA approval was granted.
2014
- USFDA approval was granted.
- IDL was granted for Brompheniramine Maleate.
2015
- EUGMP and EDQM approval was granted.
2017
- CEP (Certificate of Sustainability) was granted for Pheniramine Maleate.
- Second time USFDA approval was granted.
2018
- CEP (Certificate of Sustainability) was granted for Brompheniramine Maleate, Mepyramine Maleate and Ketamine Hydrochloride.
2020
- Third time USFDA approval was granted.
2021
- CEP (Certificate of Suitability) was granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate.
- NMPA approval was granted.
- Health Canada approval was granted.
2022
- Supriya Lifescience Limited signed a captive solar project agreement with Enrich Energy Pvt. Ltd.
2024
- Supriya Lifescience Ltd inaugurated a state-of-the-art Module E production block at Lote Parshuram, Maharashtra.
- Supriya Lifescience inaugurated a Rs 125 crore API production block at Lote Parshuram site.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800